ES2170075T3 - Vacuna de proteina m recombinante multivalente. - Google Patents

Vacuna de proteina m recombinante multivalente.

Info

Publication number
ES2170075T3
ES2170075T3 ES93922201T ES93922201T ES2170075T3 ES 2170075 T3 ES2170075 T3 ES 2170075T3 ES 93922201 T ES93922201 T ES 93922201T ES 93922201 T ES93922201 T ES 93922201T ES 2170075 T3 ES2170075 T3 ES 2170075T3
Authority
ES
Spain
Prior art keywords
multivally
vaccine
recombinant protein
streptococes
epithopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922201T
Other languages
English (en)
Inventor
James B Dale
James W Lederer Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Application granted granted Critical
Publication of ES2170075T3 publication Critical patent/ES2170075T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION ES RELATIVA A SECUENCIAS ADN QUE CODIFICAN EPITOPES QUE SE USAN EN VACUNAS HIBRIDAS DE PROTEINA RECOMBINADA MULTIVALENTE PARA CONTROLAR INFECCIONES DE ESTREPTOCOCOS DEL GRUPO A DE SEROTIPOS MULTIPLES QUE PUEDEN RESULTAR EN FIEBRE REUMATICA.
ES93922201T 1992-09-16 1993-09-15 Vacuna de proteina m recombinante multivalente. Expired - Lifetime ES2170075T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94595492A 1992-09-16 1992-09-16

Publications (1)

Publication Number Publication Date
ES2170075T3 true ES2170075T3 (es) 2002-08-01

Family

ID=25483752

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922201T Expired - Lifetime ES2170075T3 (es) 1992-09-16 1993-09-15 Vacuna de proteina m recombinante multivalente.

Country Status (10)

Country Link
US (1) US6063386A (es)
EP (1) EP0625043B1 (es)
AT (1) ATE214601T1 (es)
AU (1) AU5128493A (es)
CA (1) CA2123579C (es)
DE (1) DE69331733T2 (es)
DK (1) DK0625043T3 (es)
ES (1) ES2170075T3 (es)
IL (1) IL107025A0 (es)
WO (1) WO1994006421A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
IL107026A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Antigen of hybrid m protein and carrier for group a streptococcal vaccine
DE69331733T2 (de) * 1992-09-16 2002-08-22 The University Of Tennessee Research Corp., Knoxville Rekombinantes vielwertiges m-protein-vakzin
WO1996009395A2 (de) * 1994-09-21 1996-03-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Arzneimittel zur prophylaxe und behandlung von und diagnostika zur erkennung von autoimmunkrankheiten und viralen erkrankungen
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6716433B1 (en) 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
EP1801217A1 (en) * 1997-09-12 2007-06-27 The University of Tennessee Research Foundation Group A streptococcal vaccines
ATE349527T1 (de) * 1997-09-12 2007-01-15 Univ Tennessee Res Foundation Gruppe a streptokokken-impfstoff
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU762100B2 (en) * 1998-12-22 2003-06-19 University Of Tennessee Research Corporation, The Protective antigen of group A Streptococci (SPA)
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
DK1294771T3 (da) * 2000-06-12 2008-12-15 Univ Saskatchewan Kimært GapC-protein fra Streptococcus og anvendelse deraf til vaccinering og diagnosticering
US7160547B2 (en) 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
WO2002057315A2 (en) * 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
CA2447017A1 (en) * 2001-05-15 2002-11-21 Shire Biochem Inc. Moraxella(branhamella) catarrhalis antigens
AU2011232787B2 (en) * 2001-05-18 2013-05-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group A streptococci
WO2002094851A2 (en) * 2001-05-18 2002-11-28 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
AU2008203277B2 (en) * 2001-05-18 2011-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group A streptococci
US7270827B2 (en) 2001-10-26 2007-09-18 University Of Tennessee Research Foundation Multivalent streptococcal vaccine compositions and methods for use
US7476390B2 (en) 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20040151737A1 (en) * 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
EP1864996A1 (en) * 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.
US9289485B2 (en) * 2006-11-30 2016-03-22 Luiza Guilherme Guglielmi Therapeutic application of S. pyogenes C-terminal peptide
BRPI0604997A (pt) * 2006-11-30 2007-05-22 Fundacao Zerbini vacina contra o estreptococo beta hemolìtico do grupo a, e respectivo processo de obtenção
SI2144924T1 (sl) * 2007-04-16 2016-12-30 Minervax Aps Cepivo s fuzijskimi beljakovinami
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
MX2011004755A (es) 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
WO2014124446A1 (en) 2013-02-11 2014-08-14 University Of Tennessee Research Foundation Group a streptococcal m-related proteins and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4597967A (en) * 1982-07-27 1986-07-01 The University Of Tennessee Research Corp. Synthetic polypeptide fragments
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4521334A (en) * 1982-07-27 1985-06-04 The University Of Tennesse Research Corporation Synthetic polypeptide fragments
US4919930A (en) * 1983-06-10 1990-04-24 University Of Tennessee Research Corporation Synthetic M proteins-streptococci type 5
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US4705684A (en) * 1985-05-31 1987-11-10 The University Of Tennessee Research Corporation Synthetic M proteins - streptococci type 6
US5124153A (en) * 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
WO1993021220A1 (en) * 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
DE69331733T2 (de) * 1992-09-16 2002-08-22 The University Of Tennessee Research Corp., Knoxville Rekombinantes vielwertiges m-protein-vakzin

Also Published As

Publication number Publication date
WO1994006421A1 (en) 1994-03-31
DE69331733D1 (de) 2002-04-25
EP0625043A1 (en) 1994-11-23
AU5128493A (en) 1994-04-12
DE69331733T2 (de) 2002-08-22
CA2123579A1 (en) 1994-03-31
DK0625043T3 (da) 2002-04-22
EP0625043B1 (en) 2002-03-20
IL107025A0 (en) 1993-12-28
CA2123579C (en) 2005-05-10
EP0625043A4 (en) 1997-05-21
US6063386A (en) 2000-05-16
ATE214601T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
ES2170075T3 (es) Vacuna de proteina m recombinante multivalente.
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
ES2127829T3 (es) Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
ES2171454T3 (es) Proteinas de estres y sus usos.
DK0618813T3 (da) Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
DK52789D0 (da) Avirulente mikrober og anvendelser deraf
DK1326636T3 (da) Vaccinesammensætning
DK472988D0 (da) Terapeutiske praeparater mod streptokokinfektioner, transformerede vaerter og produkter fremstillet ved genteknologi
CY1106350T1 (el) Εμβολιο φυματιωσης
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
NO944245D0 (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
HUP9901112A2 (hu) Szintetikus HIV-gének
HUP9902438A2 (hu) Parapoxvírus vektorok
MX9307465A (es) Proteinas que tienen actividad de transferasa glicosilica.
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
AR245957A1 (es) Un dna recombinante que codifica para una proteina recombinante ligada a un soporte y un procedimiento para la fabricacion de la misma.
ES2069742T3 (es) Proteina de la capsida del calicivirus felino y secuencia nucleotida.
ES2194012T3 (es) Epitopo p1a1 y p1a2 de la gpiii a de plaquetas, su preparacion y uso.
ES2085163T3 (es) Vacunas contra los parasitos metazoos.
AR022662A1 (es) Acidos nucleicos y proteinas del gen mhp3 de mycoplasma hyopneumoniae y sus usos
DK0869184T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
AR020852A1 (es) Antigenos de vacuna de leptospira para la prevencion de leptospirosis
ES2037795T3 (es) Procedimiento para la preparacion del antigeno hrpii de plasmodium falciparum sge2.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625043

Country of ref document: ES